NovaBay Pharmaceuticals to Hold First Quarter 2016 Conference Call on May 12

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report first quarter 2016 financial results after market close on Thursday, May 12. Management will hold an investment community conference call that day to discuss financial results and provide a company update.

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time May 14, 2016, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 92879104. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the commercialization of prescription Avenova® lid and lash hygiene for the domestic eye care market. Avenova is formulated with Neutrox® which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay’s proprietary pure hypochlorous acid. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and it also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct medical salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmeriSource Bergen.

Stay informed on NovaBay's progress:Download our Mobile InvestorApp from the Apple Store or Google PlayLike us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay's Website

View source version on businesswire.com: http://www.businesswire.com/news/home/20160505005308/en/

NovaBay Contacts
For NovaBay Avenova purchasing information, please contact:
Email us
Call us: 1-800-890-0329
www.Avenova.com
or
From the Company
Thomas J. Paulson
Chief Financial Officer
510-899-8809
Contact Tom
or
Investor Contact
LHA
Jody Cain, 310-691-7100
[email protected]

Source: NovaBay Pharmaceuticals

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Phillips Edison & Company (PECO) Reports In-Line Q1 EPS, provides guidance
• MarineMax (HZO) PT Lowered to $35 at Stifel